Design (Testphase)
Risk & Weakness
Pradeep Bonde: 4% Breakout Bearish
32
Findings
July 21, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · showing the 25 strongest hits
Bonde's downside counterpart (original Stockbee formula 'c/c1 ≤ 0.96'): a daily loss of at least 4% on above-average volume (relative volume above 1) — a downside momentum burst that often triggers further weak days. Minimum daily volume 100,000 shares, price above $3 (penny-stock filter).
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(17)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth Minnow Street company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Breakout
- The price clears a level where it previously failed multiple times (top of a base, an old high) - ideally on clearly elevated volume. For many momentum strategies, the breakout is the actual buy signal.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from -100 to +100 with a school-grade rank from A+ to F. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. A/A+ are the fundamentally strongest stocks in the universe.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Momentum
- The driving force behind a price trend: stocks that have recently risen sharply statistically tend to keep rising more often than not. Momentum strategies therefore buy strength - not perceived bargains.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience, Inc. | 08/12 | — | 89 8/22 | Stage 2 | D -49 | 2 of 9 | 0.9 | Biotechnology | – | — | — | Healthcare | 25.90 $ | +37.3 % | +41.2 % | +942.3 % | −11.0 % | +38.9 % | 99 | 42 | 8.0 % | 7.7 % | 1.07 | — | 0.0 | — | 3.7 | — | — | 0.0 | — | — | 0.0 % | -38.9 % | -21.7 % | 0.02 | — | -100.0 % | 0.0 % | 0.0 % | 12.7 | 82.1 % | 5.5 % | — |
| HYLN Hyliion Holdings Corp. | 08/11 | +90 % | — | Stage 2 | C +9 | 4 of 9 | 0.0 | Auto Parts | Uses AI | — | Consumer Cyclical | 3.60 $ | +231.5 % | +141.9 % | +248.9 % | −42.8 % | +44.0 % | 98 | 50 | 13.6 % | 15.8 % | 3.47 | — | 0.0 | — | — | — | — | -0.8 | -481.7 % | 6.3 % | 0.0 % | -25.2 % | -17.5 % | — | 95.3 % | +130.3 % | 0.0 % | 0.0 % | 21.4 | 25.2 % | 7.6 % | 2.0 (1) | |
| GLUE Monte Rosa Therapeutics Inc | 08/06 | +19 % | — | Stage 2 | D -30 | 4 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 23.50 $ | +32.1 % | +35.5 % | +349.4 % | −16.0 % | +53.1 % | 96 | 50 | 8.1 % | 6.8 % | 1.56 | — | 10.9 | — | 3.4 | — | — | 51.9 | — | -238.5 % | 0.0 % | -32.6 % | -16.4 % | 0.08 | — | +63.5 % | 0.0 % | 0.0 % | 7.7 | 113.2 % | 20.7 % | — |
| NVCT Nuvectis Pharma Inc | 08/04 | +1 % | 82 7/22 | Stage 2 | E -54 | 1 of 9 | 0.9 | Biotechnology | – | — | — | Healthcare | 18.00 $ | +132.5 % | +270.0 % | +207.5 % | −0.2 % | +4.8 % | 95 | 42 | 16.4 % | 9.8 % | -0.25 | — | 0.0 | — | — | — | — | -7.4 | — | — | 0.0 % | -154.4 % | -63.6 % | — | — | -100.0 % | 0.0 % | 0.0 % | -7.1 | 18.2 % | 10.1 % | — |
| TRVI Trevi Therapeutics Inc | 08/06 | +178 % | 55 5/22 | Stage 2 | D -47 | 3 of 9 | 2.6 | Biotechnology | – | — | — | Healthcare | 16.80 $ | +38.8 % | +43.6 % | +204.7 % | −0.9 % | +32.8 % | 93 | 42 | 6.1 % | 5.0 % | 1.00 | — | 0.0 | — | — | — | — | -4.9 | 0.0 % | — | 0.0 % | -33.6 % | -23.0 % | — | 95.8 % | — | 0.0 % | 0.0 % | 25.7 | 98.3 % | 11.2 % | 1.0 (8) |
| WEST Westrock Coffee Company | 08/06 | -6 % | — | Stage 2 | D -19 | 3 of 9 | 0.0 | Packaged Foods | – | — | — | Consumer Defensive | 7.30 $ | +123.1 % | +98.3 % | +63.0 % | −2.4 % | -8.8 % | 93 | 50 | 7.4 % | 6.7 % | 0.90 | — | 0.0 | — | — | — | — | 44.0 | — | 13.0 % | -5.6 % | -24.0 % | -0.9 % | — | — | +39.8 % | 0.0 % | 0.0 % | 1.8 | 49.5 % | 13.2 % | — |
| AVTX Avalo Therapeutics Inc | 08/06 | -33 % | 41 4/22 | Stage 3 | E -67 | 2 of 9 | 1.0 | Biotechnology | – | — | — | Healthcare | 18.20 $ | -1.8 % | +2.0 % | +279.1 % | −25.8 % | +151.4 % | 91 | 42 | 7.7 % | 7.4 % | 0.79 | — | 0.0 | 9,690.0 | — | — | — | -0.2 | — | -66,988.1 % | 0.0 % | -88.8 % | -41.5 % | — | — | -86.6 % | 0.0 % | 0.0 % | -10.4 | 76.6 % | 14.1 % | — |
| KPTI Karyopharm Therapeutics Inc | 08/10 | -23 % | 94 9/22 | Stage 2 | D -25 | 4 of 9 | 0.2 | Biotechnology | Uses AI | — | — | Healthcare | 7.50 $ | +31.1 % | +35.0 % | +110.6 % | −13.9 % | +42.7 % | 89 | 42 | 7.7 % | 8.7 % | 0.81 | — | 0.0 | 1.4 | 12.1 | — | — | -1.9 | — | 13.5 % | -129.0 % | -891.1 % | -40.6 % | -0.87 | — | +0.6 % | 0.0 % | 0.0 % | -48.8 | 83.7 % | 24.8 % | — |
| ELDN Eledon Pharmaceuticals Inc | 08/13 | +58 % | 82 7/22 | Stage 2 | D -40 | 3 of 9 | 0.3 | Biotechnology | – | — | — | Healthcare | 3.90 $ | +161.6 % | +147.1 % | +52.3 % | −20.7 % | +146.6 % | 88 | 42 | 10.4 % | 7.4 % | 0.96 | — | 5.4 | — | 6.8 | — | — | 0.8 | — | — | 0.0 % | -72.7 % | -35.1 % | 0.01 | — | -100.0 % | 0.0 % | 0.0 % | -0.3 | 59.2 % | 9.7 % | — |
| KYMR Kymera Therapeutics Inc | 08/10 | +109 % | 54 5/22 | Stage 2 | D -29 | 4 of 9 | 9.7 | Biotechnology | – | — | — | Healthcare | 111.10 $ | +26.3 % | +31.5 % | +115.8 % | −10.5 % | +6.3 % | 87 | 42 | 8.9 % | 6.0 % | 1.96 | — | 0.0 | 187.9 | 5.3 | — | — | -9.5 | -244.9 % | -549.8 % | 0.0 % | -27.1 % | -17.2 % | 0.05 | 92.3 % | -16.7 % | 0.0 % | 0.0 % | 14.7 | 117.6 % | 15.6 % | 1.2 (20) |
| AVBP ArriVent BioPharma, Inc. Common St | 08/10 | — | 55 5/22 | Stage 2 | D -26 | 2 of 9 | 1.5 | Biotechnology | – | — | — | Healthcare | 28.20 $ | +67.7 % | +54.2 % | +40.4 % | −2.6 % | +29.0 % | 87 | 42 | 6.0 % | 5.9 % | 1.30 | — | 0.0 | — | 4.9 | — | — | 0.0 | — | — | 0.0 % | -55.2 % | -34.7 % | 0.00 | — | — | 0.0 % | 0.0 % | 15.6 | 95.9 % | 17.9 % | — |
| MNPR Monopar Therapeutics Inc | 08/11 | -10 % | 89 8/22 | Stage 3 | D -38 | 4 of 9 | 0.5 | Biotechnology | – | — | — | Healthcare | 105.90 $ | +25.2 % | +33.6 % | +179.6 % | −16.5 % | +29.7 % | 87 | 42 | 8.6 % | 7.6 % | 1.48 | — | 0.0 | — | 4.3 | — | — | -2.4 | — | — | 0.0 % | -15.9 % | -12.1 % | 0.00 | — | -100.0 % | 0.0 % | 0.0 % | 62.2 | 93.3 % | 34.1 % | — |
| SION Sionna Therapeutics, Inc. Common Stock | 08/10 | — | — | Stage 2 | D -31 | 1 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 45.70 $ | -3.1 % | -2.4 % | +191.4 % | −11.7 % | +20.6 % | 85 | 50 | 7.2 % | 7.1 % | — | — | 0.0 | — | 6.7 | — | — | 0.0 | — | — | 0.0 % | -26.7 % | -18.3 % | 0.03 | — | — | 0.0 % | 0.0 % | 20.9 | 100.3 % | 18.0 % | — |
| BEAM Beam Therapeutics Inc | 08/04 | +2 % | 39 4/22 | Stage 2 | C +6 | 4 of 9 | 3.6 | Biotechnology | – | — | — | Healthcare | 26.30 $ | +19.8 % | +24.2 % | +102.9 % | −8.0 % | +50.5 % | 83 | 42 | 7.7 % | 7.2 % | 2.18 | — | 0.0 | 21.7 | 3.0 | — | — | -7.0 | -337.8 % | -146.9 % | -40.2 % | -5.8 % | -15.8 % | 0.22 | 78.6 % | +120.0 % | 0.0 % | 0.0 % | 8.3 | 107.0 % | 42.6 % | 1.2 (17) |
| ANNX Annexon Inc | 08/13 | +17 % | 15 2/22 | Stage 1 | D -50 | 1 of 9 | 0.8 | Biotechnology | – | — | — | Healthcare | 5.60 $ | +5.2 % | +7.5 % | +122.7 % | −28.3 % | +154.9 % | 82 | 42 | 7.4 % | 6.6 % | 1.17 | — | 0.0 | — | — | — | — | -2.5 | — | — | 0.0 % | -87.6 % | -45.3 % | — | — | — | 0.0 % | 0.0 % | -5.2 | 102.7 % | 17.2 % | — |
| STOK Stoke Therapeutics Inc | 08/11 | +60 % | 56 5/22 | Stage 1 | D -33 | 1 of 9 | 1.9 | Biotechnology | – | — | — | Healthcare | 27.70 $ | -2.0 % | +0.7 % | +162.2 % | −24.4 % | +48.4 % | 79 | 42 | 5.1 % | 4.9 % | 1.18 | — | 204.1 | 59.3 | 5.0 | — | — | 52.5 | -857.6 % | 100.0 % | 0.0 % | -45.6 % | -27.2 % | 0.01 | 89.1 % | +404.5 % | 0.0 % | 0.0 % | 10.1 | 120.3 % | 19.6 % | 1.1 (10) |
| SRRK Scholar Rock Holding Corp | 08/05 | +8 % | 26 3/22 | Stage 2 | D -34 | 1 of 9 | 6.4 | Biotechnology | – | — | — | Healthcare | 50.70 $ | +16.4 % | +19.8 % | +57.2 % | −0.1 % | +10.3 % | 77 | 42 | 4.7 % | 4.7 % | 0.68 | — | 0.0 | — | 23.7 | — | — | -2.1 | 0.0 % | — | 0.0 % | -138.9 % | -54.3 % | 0.75 | 51.6 % | -100.0 % | 0.0 % | 0.0 % | -3.7 | 116.6 % | 17.5 % | 1.0 (10) |
| CTNM Contineum Therapeutics, Inc. Class A Common Stock | 08/04 | — | 82 7/22 | Stage 1 | D -40 | 4 of 9 | 0.5 | Biotechnology | – | — | — | Healthcare | 13.50 $ | +4.2 % | +18.3 % | +211.2 % | −18.2 % | +67.2 % | 72 | 42 | 9.4 % | 7.3 % | 0.70 | — | 0.0 | — | 2.0 | — | — | 20.8 | — | — | 0.0 % | -26.9 % | -18.2 % | 0.03 | — | -100.0 % | 0.0 % | 0.0 % | 28.8 | 94.0 % | 5.1 % | — |
| AMBP Ardagh Metal Packaging SA | 07/23 | +30 % | — | Stage 2 | C +5 | 4 of 9 | 0.0 | Packaging & Containers | – | — | — | Consumer Cyclical | 4.50 $ | +17.2 % | +18.7 % | +18.0 % | −10.5 % | +0.0 % | 61 | 50 | 3.7 % | 3.2 % | 0.53 | — | 19.3 | — | 94.3 | — | — | 20.9 | — | 12.6 % | 0.2 % | -63.6 % | 3.4 % | -6.42 | — | +12.0 % | 8.3 % | 1.7 % | 2.9 | 21.0 % | 6.4 % | — |
| EYPT Eyepoint Pharmaceuticals Inc | 08/05 | -8 % | 69 6/22 | Stage 1 | D -32 | 1 of 9 | 1.2 | Biotechnology | – | — | — | Healthcare | 12.70 $ | -21.3 % | -22.7 % | +73.9 % | −28.3 % | +191.8 % | 59 | 42 | 6.7 % | 6.3 % | 1.74 | — | 6.2 | 151.8 | 5.0 | — | — | 11.6 | — | -2,951.8 % | 0.0 % | -102.7 % | -54.1 % | 0.09 | — | -27.5 % | 0.0 % | 0.0 % | -7.3 | 111.8 % | 19.0 % | — |
| AQST Aquestive Therapeutics Inc | 08/10 | +58 % | 28 3/22 | Stage 3 | C -7 | 3 of 9 | 0.6 | Drug Manufacturers - Special | – | — | — | Healthcare | 3.90 $ | -22.1 % | -30.3 % | +51.7 % | −40.9 % | +99.3 % | 59 | 42 | 6.5 % | 5.1 % | 1.45 | — | 0.0 | 11.1 | 14.2 | — | — | -1.8 | — | 63.4 % | -137.1 % | 0.0 % | -28.7 % | -3.92 | — | -22.6 % | 0.0 % | 0.0 % | -5.4 | 60.6 % | 12.4 % | — |
| HROW Harrow Health Inc | 08/10 | +44 % | 55 5/22 | Stage 3 | D -29 | 2 of 9 | 1.5 | Drug Manufacturers - Special | – | — | — | Healthcare | 44.50 $ | -12.7 % | -18.0 % | +37.7 % | −24.3 % | +63.3 % | 58 | 26 | 5.1 % | 5.4 % | 0.26 | — | 285.7 | 5.7 | 54.6 | 107.8 | — | 55.3 | — | 74.1 % | -5.6 % | -35.4 % | 3.1 % | 10.47 | — | +36.4 % | 0.0 % | 0.0 % | 4.2 | 58.9 % | 21.8 % | — |
| PLTK Playtika Holding Corp | 08/06 | -20 % | 75 7/24 | Stage 3 | D -16 | 4 of 9 | 1.2 | Electronic Gaming & Multimed | – | — | — | Communication Services | 3.80 $ | +0.0 % | -1.5 % | -10.7 % | −28.5 % | +39.8 % | 58 | 52 | 7.5 % | 5.8 % | 1.09 | — | 5.1 | 0.4 | 0.0 | 2.2 | 1.52 | 43.0 | — | 73.0 % | -10.5 % | 0.0 % | 5.4 % | -5.44 | — | +8.1 % | 10.4 % | 41.2 % | 2.0 | 16.2 % | 9.6 % | — |
| KRRO Korro Bio, Inc. | 08/11 | -19 % | 57 5/22 | Stage 3 | E -53 | 2 of 9 | 0.2 | Biotechnology | – | — | — | Healthcare | 11.50 $ | +71.2 % | +56.9 % | +17.2 % | −78.2 % | +64.3 % | 54 | 42 | 10.9 % | 10.0 % | 2.11 | — | 0.0 | 45.6 | 1.5 | — | — | -5.6 | — | -1,153.9 % | 0.0 % | -87.8 % | -26.8 % | 0.36 | — | +181.5 % | 0.0 % | 0.0 % | -1.2 | 96.9 % | 10.3 % | — |
| EVMN Evommune, Inc. | 08/06 | — | 89 8/22 | Stage 2 | D -36 | 4 of 9 | 0.9 | Biotechnology | – | — | — | Healthcare | 11.50 $ | +41.6 % | -14.4 % | — | −27.3 % | +29.1 % | 54 | 42 | 10.8 % | 7.9 % | — | — | 0.0 | — | 2.9 | — | — | 0.0 | — | 100.0 % | 0.0 % | -45.0 % | -29.7 % | 0.03 | — | +85.7 % | 0.0 % | 0.0 % | 21.3 | 110.8 % | 17.6 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Bonde's downside counterpart (original Stockbee formula 'c/c1 ≤ 0.96'): a daily loss of at least 4% on above-average volume (relative volume above 1) — a downside momentum burst that often triggers further weak days. Minimum daily volume 100,000 shares, price above $3 (penny-stock filter).
All scanners are recalculated daily across the entire stock universe — most recently on 21. July 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 32 stocks pass this scanner's criteria (as of 21. July 2026). The 25 strongest hits are shown.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Altman Z: Distress Zone
- Below the 50- & 200-SMA
- Beneish M-Score
- Downward Momentum
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- Kathy Donnelly: Liquid Movers Down
- Mike Webster: Overextended (Webby RSI)
- Near 52-Week Low
- Pradeep Bonde: $ Breakout Bearish
- Qullamaggie: Parabolic (Short-Watch)
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Insolvency Candidate
- Weakness Cluster
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.